NexturnBioscience Co. Ltd (089140) — Cash Flow-to-Debt Ratio
NexturnBioscience Co. Ltd (089140) has a Cash Flow-to-Debt Ratio of 0.04x as of September 2025, meaning its operating cash flow of ₩4.51 Billion could theoretically repay 0% of its total liabilities (₩128.65 Billion) in one year. See NexturnBioscience Co. Ltd (089140) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
NexturnBioscience Co. Ltd Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for NexturnBioscience Co. Ltd across 11 annual periods. Also explore 089140 net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for NexturnBioscience Co. Ltd (2014–2024)
Year-by-year debt coverage analysis for NexturnBioscience Co. Ltd. For market capitalisation and broader financial context, see 089140 market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.01x | ₩-1.14 Billion | ₩96.41 Billion | ▲ +36.2% |
| 2023 | -0.02x | ₩-1.97 Billion | ₩105.98 Billion | ▼ -43.6% |
| 2022 | -0.01x | ₩-1.19 Billion | ₩91.98 Billion | ▼ -116.3% |
| 2021 | 0.08x | ₩3.66 Billion | ₩46.21 Billion | ▼ -13.2% |
| 2020 | 0.09x | ₩235.94 Million | ₩2.58 Billion | ▼ -83.3% |
| 2019 | 0.55x | ₩2.74 Billion | ₩5.01 Billion | ▲ +2.1% |
| 2018 | 0.53x | ₩9.63 Billion | ₩18.01 Billion | ▼ -68.6% |
| 2017 | 1.70x | ₩5.08 Billion | ₩2.99 Billion | ▼ -17.8% |
| 2016 | 2.07x | ₩17.88 Billion | ₩8.64 Billion | ▲ +242.1% |
| 2015 | 0.60x | ₩1.92 Billion | ₩3.17 Billion | ▼ -58.9% |
| 2014 | 1.47x | ₩6.48 Billion | ₩4.41 Billion | — |